These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35476257)

  • 1. Quality of life after long-term biochemical control of acromegaly.
    Kimball A; Dichtel LE; Yuen KCJ; Woodmansee WW; Haines MS; Nachtigall LB; Swearingen B; Jones P; Tritos NA; Sharpless JL; Kaiser UB; Gerweck A; Miller KK
    Pituitary; 2022 Jun; 25(3):531-539. PubMed ID: 35476257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders.
    Valassi E; Brick DJ; Johnson JC; Biller BM; Klibanski A; Miller KK
    Endocr Pract; 2012; 18(2):209-18. PubMed ID: 22440981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly.
    Dichtel LE; Kimball A; Yuen KCJ; Woodmansee W; Haines MS; Guan QX; Swearingen B; Nachtigall LB; Tritos NA; Sharpless JL; Kaiser UB; Gerweck AV; Miller KK
    Clin Endocrinol (Oxf); 2021 Jan; 94(1):58-65. PubMed ID: 32779234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study.
    Kyriakakis N; Lynch J; Gilbey SG; Webb SM; Murray RD
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):806-815. PubMed ID: 28316090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly.
    Wexler T; Gunnell L; Omer Z; Kuhlthau K; Beauregard C; Graham G; Utz AL; Biller B; Nachtigall L; Loeffler J; Swearingen B; Klibanski A; Miller KK
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2471-7. PubMed ID: 19366847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL.
    Yoshida K; Fukuoka H; Matsumoto R; Bando H; Suda K; Nishizawa H; Iguchi G; Ogawa W; Webb SM; Takahashi Y
    Pituitary; 2015 Dec; 18(6):876-83. PubMed ID: 26123761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acromegaly improves quality of life, measured by AcroQol.
    Paisley AN; Rowles SV; Roberts ME; Webb SM; Badia X; Prieto L; Shalet SM; Trainer PJ
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):358-62. PubMed ID: 17555502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Life and its Determinants in Patients With Treated Acromegaly: A Cross-Sectional Nationwide Study in China.
    Guo X; Wang K; Yu S; Gao L; Wang Z; Zhu H; Xing B; Zhang S; Dong D
    J Clin Endocrinol Metab; 2021 Jan; 106(1):211-225. PubMed ID: 33079177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly.
    van der Klaauw AA; Biermasz NR; Hoftijzer HC; Pereira AM; Romijn JA
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):123-8. PubMed ID: 18182092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire.
    Rowles SV; Prieto L; Badia X; Shalet SM; Webb SM; Trainer PJ
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3337-41. PubMed ID: 15755865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects.
    Malik IA; Foy P; Wallymahmed M; Wilding JP; MacFarlane IA
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):75-81. PubMed ID: 12807507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT Study).
    Arshad MF; Ogunleye O; Ross R; Debono M
    Pituitary; 2021 Oct; 24(5):768-777. PubMed ID: 33982222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influences on quality of life in GH deficient adults and their effect on response to treatment.
    Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Smethurst LE; Shalet SM
    Clin Endocrinol (Oxf); 1999 Nov; 51(5):565-73. PubMed ID: 10594517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The "quality of life-assessment of growth hormone deficiency in adults" questionnaire: can it be used to assess quality of life in hypopituitarism?
    Barkan AL
    J Clin Endocrinol Metab; 2001 May; 86(5):1905-7. PubMed ID: 11344182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between pain, arthropathy and health-related quality of life in patients suffering from acromegaly. A cross-sectional study.
    Alito A; Basile GC; Bruschetta D; Berescu GL; Cavallaro F; Postorino AD; Scarcella E; Ragonese M; Cannavò S; Tisano A
    Folia Med (Plovdiv); 2023 Feb; 65(1):37-45. PubMed ID: 36855972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study.
    Bolanowski M; Hubalewska-Dydejczyk A; Kos-Kudła B; Ruchała M; Witek P; Zgliczyński W; Houchard A; Bartmańska M
    Endokrynol Pol; 2021; 72(5):512-519. PubMed ID: 34647602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Klotho: a possible predictor of quality of life in acromegaly patients.
    Coopmans EC; El-Sayed N; Frystyk J; Magnusson NE; Jørgensen JOL; van der Lely AJ; Janssen JAMJL; Muhammad A; Neggers SJCMM
    Endocrine; 2020 Jul; 69(1):165-174. PubMed ID: 32333268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
    Caron PJ; Bevan JS; Petersenn S; Houchard A; Sert C; Webb SM;
    Pituitary; 2016 Apr; 19(2):149-57. PubMed ID: 26603536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in transition phase in adolescents and young adults with severe and partial growth hormone deficiency.
    Oswiecimska JM; Roczniak W; Romanowicz D; Szymlak A; Mikolajczak A; Malczyk Z; Stojewska M; Ziora KT
    Neuro Endocrinol Lett; 2014; 35(8):676-83. PubMed ID: 25702295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test.
    Tiemensma J; Pereira AM; Romijn JA; Broadbent E; Biermasz NR; Kaptein AA
    Eur J Endocrinol; 2015 May; 172(5):583-93. PubMed ID: 25724922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.